Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Recent Advancements in CNS Acting Drugs: A Step Towards End of Illness

Author(s): Md. Noushad Javed, Faheem Hyder Pottoo, Mohd. Javed Naim and Pooja A. Chawla*

Volume 21, Issue 10, 2022

Published on: 22 July, 2022

Page: [882 - 883] Pages: 2

DOI: 10.2174/187152732110220722112205

conference banner
Abstract

Progressive degeneration in the morphology and functions of neuronal cells leads to multifactorial pathogenesis conditions of oxidative stress, mitochondrial dysfunction, excitotoxicity, nitric oxide toxicity, and neuro-inflammation to mediate heterogeneous types of neurodegenerative diseases, such as Epilepsy, Alzheimer's (AD) and Parkinson's (PD), more prominently among aging populations. In this editorial, complex mechanisms, challenges, and advancements made in the discovery of new neurotherapeutics, as well as designing approaches being adopted to fabricate brain-targeted delivery systems, are discussed.

« Previous Next »
[1]
Verma R, Vyas P, Kaur J, et al. Approaches for Ear-targeted Delivery Systems in Neurosensory Disorders to avoid Chronic Hearing Loss Mediated Neurological Diseases. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 2022; 21(6): 479-91.
[2]
Javed MN, Dahiya ES, Ibrahim AM, Alam M, Khan FA, Pottoo FH. Recent advancement in clinical application of nanotechnological approached targeted delivery of herbal drugs.Nanophytomedicine. Singapore: Springer 2020; pp. 151-72.
[3]
Saha P, Bose S, Javed MN, Srivastava AK. Clinical potential of nanotechnlogy as smart therapeutics: A step toward targeted drug delivery.In Advances in Nanotechnology-Based Drug Delivery Systems. Elsevier 2022; pp. 133-54.
[4]
Aslam M, Javed M, Deeb HH, et al. Lipid Nanocarriers for Neurotherapeutics: Introduction, Challenges, Blood-brain Barrier, and Promises of Delivery Approaches. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets- CNS & Neurological Disorders) 2022; 21(10): 952-65.
[5]
Jahangir MA, Jain P, Verma R, et al. Transdermal Nutraceuticals Delivery System for CNS Disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 2022; 21(10): 977-94.
[6]
Kumari N, Daram N, Alam MS, Verma AK. Rationalizing the Use of Polyphenol Nano-formulations in the Therapy of Neurodegenerative Diseases. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 2022; 21(10): 966-76.
[7]
Ali OA, Shaikh M, Hasnain MS, Sami F, Khan A, Ansari MT. Nanotechnological Advances in the Treatment of Epilepsy. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 2022; 21(10): 977-93.
[8]
Rafiullah M, Siddiqui K. Pharmacological Treatment of Diabetic Peripheral Neuropathy: An Update. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 2022; 21(10): 884-900.
[9]
Pandey M, Saleem S, Nautiyal H, Pottoo FH, Javed MN. PINK1/Parkin in neurodegenerative disorders: crosstalk between mitochondrial stress and neurodegeneration. In Quality control of cellular protein in neurodegenerative disorders 2020. (pp. 282-301). IGI Global.
[10]
Verma RK, Pandey M, Chawla P, et al. An insight into the role of Artificial Intelligence in the early diagnosis of Alzheimer’s disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets- CNS & Neurological Disorders) 2022; 21(10): 901-12.
[11]
Das S, Akbar S, Ahmed B, et al. Recent Advancement of Pyrazole Scaffold Based Neuroprotective Agents: A Review. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 2022; 21(10): 940-51.
[12]
Das S, Akbar S, Ahmed B, et al. Structural Activity Relationship based Medicinal Perspectives of Pyrimidine Derivatives as Anti-Alzheimer’s Agents: A Comprehensive Review. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets- CNS & Neurological Disorders) 2022; 21(10): 926-39.
[13]
Kumar A, Walia H, Pottoo FH, Javed M. Insights of nanophytomedicines as a combinatorial therapy in disease diagnosis and treatment.In Nanophytomedicine. Singapore: Springer 2020; pp. 113-32.
[14]
Datusalia AK, Singh G, Yadav N, Gaun S, Manik M, Singh RK. Targeted Delivery of Montelukast for the Treatment of Alzheimer’s Disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 2022; 21(10): 913-25.

Rights & Permissions Print Cite
Article Metrics
18
© 2024 Bentham Science Publishers | Privacy Policy